OpenDNA

Company Overview

Snapshot

Founded in September 2018 by Eran Feldhay and Erez Ornan, OpenDNA operates with 1–10 employees. The company has raised $2.45M across five funding rounds. In November 2023, OpenDNA partnered with PartnerMD to integrate its AI-based genetic risk testing for cardiometabolic diseases, marking a significant commercial expansion.

Business overview

OpenDNA is an Israeli Health Tech & Life Sciences company developing an AI platform that integrates clinical and genomic data analysis to predict and prevent polygenic diseases. Its core technology leverages artificial intelligence and machine learning, specifically focusing on genes, to create prediction models that identify high-risk patients and inform targeted prevention strategies. The company's solutions are currently applied to cardiometabolic syndrome, with plans to expand into other complex polygenic disease states like cancer, chronic kidney failure, and autoimmune, neurological, and musculoskeletal diseases. OpenDNA serves healthcare providers and insurance companies in the Digital Healthcare sector, operating in the Medical Decision Support category.

Strategic signal

In November 2023, OpenDNA announced a strategic partnership with PartnerMD to provide AI-based genetic risk testing for cardiometabolic diseases. This collaboration is a strong signal of commercial validation and market adoption for OpenDNA's precision genomic AI platform, indicating a significant step towards integrating its technology into broader clinical practice and expanding its reach within the US healthcare market.

Company Intelligence Q&A

What is OpenDNA's primary focus?

OpenDNA focuses on using Precision Genomic AI to predict and prevent heart disease by combining clinical and genomic data analysis for polygenic diseases.

When was OpenDNA founded and by whom?

OpenDNA was founded in September 2018 by Eran Feldhay and Erez Ornan.

What was a key partnership announced by OpenDNA in late 2023?

In November 2023, OpenDNA partnered with PartnerMD to provide patients with AI-based genetic risk testing for cardiometabolic diseases.

What was the outcome of OpenDNA's clinical study in 2023?

In June 2023, OpenDNA announced the successful conclusion of a 150-patient clinical study.

What significant research agreement did OpenDNA announce in 2022?

In March 2022, OpenDNA announced a know-how and research agreement with Mayo Clinic as part of a pilot clinical study for cardiovascular disease prevention.